Navigation Links
MedImmune Licenses Reverse Genetics Technology to Hungary's Omninvest for Use in Influenza Vaccine Development and Production
Date:10/16/2008

Second Agreement Signed in Third Quarter of 2008 Expands Worldwide

Application of Cutting-Edge Influenza Vaccine Technology

GAITHERSBURG, Md., Oct. 16 /PRNewswire/ -- MedImmune announced today that it has licensed its proprietary reverse genetics intellectual property to Omninvest, a Hungarian research and manufacturing company, to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only with segments of the virus's genome. This announcement marks the second agreement of this kind that MedImmune signed in the third quarter of 2008.

"Omninvest has demonstrated decades of commitment to providing protection against influenza, and we commend their commitment to donate some of their product to the World Health Organization (WHO) stockpile for distribution among developing nations," said MedImmune's Jonathan Klein-Evans, vice president, intellectual property. "MedImmune is pleased to license our reverse genetics technology to Omninvest as we have done previously to five other influenza vaccine manufacturers."

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of key patent estates for use of the rev
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
2. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
3. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
4. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
5. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
6. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
7. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
8. Seneca Valley High School Student Receives Science Award From MedImmune
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... that it has been granted a patent by ... its unique delivery system for delivering its "original" ... for the treatment of diseases with an inflammatory ...
(Date:9/17/2014)... Cary, N.C. (PRWEB) September 17, 2014 ... solutions that advances science and healthcare, has renewed its ... term. , As part of the agreement, Personify will ... with a sustained emphasis on recruitment analytics, including time-to-fill, ... decision to renew our agreement with Personify was based ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
(Date:9/17/2014)... Wilmington, DE (PRWEB) September 17, 2014 ... profit organization committed to lowering the barriers to ... has announced the appointment of Carmen Nitsche as ... organization looks to expand its global reach. , ... she was Vice President, Corporate Development. At Accelrys, ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... SAN DIEGO, July 28, 2011 Gen-Probe Incorporated (NASDAQ: ... quarter of 2011, with total revenues of $135.9 million and ... "Gen-Probe posted record sales of APTIMA women,s health products in ... blood screening revenue to decline compared to strong sales a ...
... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... the second quarter of 2011, the Company reported net income of ... of $5.2 million, or $0.09 loss per share, for the same ... the Company reported net income of $4.9 million, or $0.09 per ...
... ITMN ) today announced that it will release its ... A live conference call and webcast will be hosted by ... discuss business highlights and financial results for the second quarter ... the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ...
Cached Biology Technology:Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14Neurocrine Biosciences Reports Second Quarter 2011 Results 2Neurocrine Biosciences Reports Second Quarter 2011 Results 3Neurocrine Biosciences Reports Second Quarter 2011 Results 4Neurocrine Biosciences Reports Second Quarter 2011 Results 5Neurocrine Biosciences Reports Second Quarter 2011 Results 6Neurocrine Biosciences Reports Second Quarter 2011 Results 7InterMune to Release Second Quarter Financial Results on August 4 2
(Date:9/16/2014)... severe maternal morbidity amongst women in Australia is ... study published today (17 September) in BJOG: ... , Australians generally enjoy high standards of living; ... exist, in particular between indigenous and non indigenous ... the independent impact of socioeconomic position on severe ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... Biobanks are repositories for tissue samples, usually in ... from surgical procedures. These samples are collected and used ... linked to personal health information regarding the sample donor. ... researchers who want to use them face important questions ...
... The Life Sciences Discovery Fund (LSDF) today announced awards ... therapies and key resources for medical researchers and health-care ... the three programs. The programs will be led ... across the state. Dr. David Flum will work with ...
... MADISON, WI, JUNE 28, 2011 -- The ... provides information needed to sustainably manage agroforestry systems. ... increase yields and also reduce financial and environmental ... that allows for site-specific evaluation of nutrient-production imbalances ...
Cached Biology News:Public prefers limited informed consent process for biobanks 2Public prefers limited informed consent process for biobanks 3Life Sciences Discovery Fund helps launch 3 programs to advance health research and development 2Analyzing agroforestry management 2
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides) and PDMS Stamps (3 PDMS micropatterned ... or 100 um x 10 mm or 200 um ...
LTBP-1 (E-20)...
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Biology Products: